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Metabolic network as an objective 
biomarker in monitoring deep brain stimulation 
for Parkinson’s disease: a longitudinal study
Jingjie Ge1†, Min Wang2†, Wei Lin3†, Ping Wu1, Yihui Guan1, Huiwei Zhang1, Zhemin Huang1, Likun Yang3, 
Chuantao Zuo1,4*† , Jiehui Jiang2,5*† , Axel Rominger6 and Kuangyu Shi6,7
Abstract 
Background: With the advance of subthalamic nucleus (STN) deep brain stimulation (DBS) in the treatment of Par-
kinson’s disease (PD), it is desired to identify objective criteria for the monitoring of the therapy outcome.This paper 
explores the feasibility of metabolic network derived from positron emission tomography (PET) with 18F-fluorodeoxy-
glucose in monitoring the STN DBS treatment for PD.
Methods: Age-matched 33 PD patients, 33 healthy controls (HCs), 9 PD patients with bilateral DBS surgery and 9 
controls underwent 18F-FDG PET scans. The DBS patients were followed longitudinally to investigate the alternations 
of the PD-related metabolic covariance pattern (PDRP) expressions.
Results: The PDRP expression was abnormally elevated in PD patients compared with HCs (P < 0.001). For DBS 
patients, a significant decrease in the Unified Parkinson’s Disease Rating Scale (UPDRS, P = 0.001) and PDRP expression 
(P = 0.004) was observed 3 months after STN DBS treatment, while a rollback was observed in both UPDRS and PDRP 
expressions (both P < 0.01) 12 months after treatment. The changes in PDRP expression mediated by STN DBS were 
generally in line with UPDRS improvement. The graphical network analysis shows increased connections at 3 months 
and a return at 12 months confirmed by small-worldness coefficient.
Conclusions: The preliminary results demonstrate the potential of metabolic network expression as complimentary 
objective biomarker for the assessment and monitoring of STN DBS treatment in PD patients.
Clinical Trial Registration ChiCTR-DOC-16008645. http://www.chict r.org.cn/showp roj.aspx?proj=13865 .
Keywords: PD-related metabolic network pattern, Spatial covariance analysis, Parkinson’s disease, Deep brain 
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Introduction
Since it was introduced in the early 1990s, deep brain 
stimulation (DBS) has become the second milestone in 
the treatment of Parkinson’s disease (PD) after dopamine 
replacement therapy. High-frequency stimulation with 
DBS targeting the subthalamic nucleus (STN) has proven 
to effectively improve motor dysfunction in PD patients. 
Prospective multicenter studies have reported that the 
Unified Parkinson’s Disease Rating Scale (UPDRS) score 
6  months after the first lead implantation was reduced 
by 23% compared to baseline in off-medication condi-
tions [1], with the most significant amelioration occur-
ring in tremor, rigidity and bradykinesia [2]. However, the 
UPDRS is a subjective criteria, which varies by different 
examiners [3]. It is also influenced by the background 
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and status of patients such as educational level, age and 
cultural differences [4]. This becomes more difficult for 
the assessment of DBS treatment, which may be biased 
from psychological and physical fatigue, depression, and 
side effects caused by drugs of patients [5]. The possible 
deviation may hamper the optimization of DBS treat-
ment. Therefore, an objective biomarker is desired for the 
assessment and monitoring of DBS treatment.
Functional imaging techniques such as metabolic brain 
imaging with 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) could provide an objective 
way to map and quantify changes in local neural activ-
ity associated with brain diseases. In particular, abnor-
mal PD-related metabolic covariance patterns (PDRP) 
have typically been identified by spatial covariance analy-
sis, whose expression yields the better discrimination of 
PD patients at an individual level. It has been reported 
that PDRP activities could accurately discriminate PD 
patients not only from controls but also from individu-
als with atypical Parkinsonism (i.e., multiple system atro-
phy or progressive supranuclear palsy) [6]. Moreover, the 
increased expression of PDRP revealed consistent corre-
lation with motor manifestations [7] and was useful for 
detecting the prodromal stage of parkinsonism (i.e., rapid 
eye movement sleep behavior disorder) by predicting 
phenoconversion toward subsequent development [8, 9]. 
However, few studies explored whether the PDRP expres-
sion could be used to measure the therapy outcome of 
STN DBS for PD at an individual level.
PDRP activities have also been shown to character-
ize alterations in cerebral metabolic function linking the 
treatment outcomes in PD patients. Indeed, inhibited 
PDRP activities were observed to be induced by STN 
DBS as demonstrated by decreased metabolism in the 
putamen/globus pallidus, sensorimotor cortex and cer-
ebellar vermis, covarying with increased metabolism 
in the precuneus, which indicated a potential correla-
tion between ameliorated motor symptoms and the cor-
rected function underlying the abnormally overexpressed 
circuits of the cortico-striato-pallido-thalamo-cortical 
(CSPTC) pathway for motor control in PD patients [10]. 
It is notable that these investigations directly compared 
STN DBS “ON” and “OFF” states at the same time point 
after electrode implantation, critically reflecting the 
immediate interference of external local stimuli on the 
whole brain [5, 10]. The immediate interference of DBS 
may be effected by the after discharge of neurostimula-
tion, and the observation of DBS “OFF” is controversial 
with DBS long-term potentiation [11].
Therefore, the purpose of the current study was to 
examine whether the PDRP expression could be as 
a potential objective biomarker for monitoring STN 
DBS treatment outcome, for which we conducted a 
longitudinal follow-up study comparing 18F-FDG PET 
imaging in the same patients at different time points 
(baseline, 3  months and 12  months) before and after 
treatment. In addition to examine the feasibility of PDRP 
expression, this study also investigated the underlying 
connectome to elucidate the efficiency of PDRP. The con-
nections can provide an in-depth insight into disease-
associated abnormalities and therapy-induced effects 
within ROIs of PDRP [12–14]. Graph theory was applied 
to investigate the topology of disease networks within 
PDRP [15], and exaggerated small-world properties were 
revealed.
Methods
Subjects
We investigated two independent cohorts of subjects 
with 18F-FDG PET images in this study (Table 1). Cohort 
I comprised 33 PD patients (PD1) and 33 age-/gender-
matched healthy controls (HC1) recruited from Huashan 
Hospital, Fudan University, Shanghai, China. The scans 
from cohort I were used for the identification of region-
of-interest (ROI)-based PDRP topography. Cohort II 
included 9 PD patients (PD2) and 9 age-/gender-matched 
healthy controls (HC2) recruited from 904 Hospital, 
Wuxi, China. Each PD patient from cohort II underwent 
bilateral STN DBS implantation. Four of the 9 patients 
were scanned 3 times with 18F-FDG PET images (preop-
erative baseline, 3-month post-operation and 12-month 
post-operation), while the other 5 patients were scanned 
twice (preoperative baseline and 3-month post-oper-
ation). Of the 5 subjects who did not complete the final 
follow-up, 2 relocated and 3 refused to participate in fur-
ther scanning. Imaging data from cohort II were used to 
assess the effects of clinically effective STN DBS on the 
metabolic variation in PD patients.
All PD patients enrolled in this study satisfied the 
diagnostic criteria according to the United Kingdom 
Parkinson’s Disease Society Brain Bank and showed 
no structural brain abnormalities (e.g., mass lesions or 
ischemia) on magnetic resonance imaging (MRI) scans 
[16]. Each PD patient was evaluated by the Unified Par-
kinson’s Disease Rating Scale (UPDRS) by a senior move-
ment disorder specialist on the same day where 18F-FDG 
PET images were acquired, at least 12  h after the ces-
sation of oral antiparkinsonian medication. For PD2 
patients, PET images and clinical evaluation were con-
ducted in the STN DBS “OFF” state, in the absence of 
STN stimulation at least 2 h prior to PET imaging at all 
time points [17]. The PD2 patients were at very advanced 
clinical stages compared to PD1 patients with longer dis-
ease durations (P = 0.001) and more severe motor symp-
toms (P < 0.001) (Table 1). All healthy control participants 
in this study underwent a neurological examination to 
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rule out a history of neurological or psychiatric disorders. 
None of the patients or healthy subjects had any prior 
exposure to neuroleptic agents or drug use.
Ethical permission for the study procedures was 
obtained from the Institutional Review Boards at 
Huashan Hospital and 904 Hospital. This study was per-
formed in compliance with the Code of Ethics of the 
World Medical Association (Declaration of Helsinki) and 
the standards established by the author’s local Institu-
tional Review Boards and grant agencies. Written con-
sent was obtained at each institution from each subject 
following a detailed explanation of the scanning pro-
cedures. Authors had access to information that could 
identify individual participants during or after data col-
lection. All procedures performed in studies involving 
human participants were in accordance with the ethical 
standards of the institutional and/or national research 
committee and with the 1964 Declaration of Helsinki and 
its later amendments or comparable ethical standards.
STN DBS
The 9 PD patients who underwent DBS surgery received 
bilateral electrodes (Model 3389, Medtronic, USA) 
implanted in the STN at 904 Hospital, Wuxi, China. The 
installation of a Leksell stereotaxic frame was performed 
under local anesthesia. Stereotactic MRI was used during 
surgery for both preoperative targeting and immediate 
post-operative verification, verifying correct electrode 
placement within the STN. Stimulation parameters (fre-
quency, pulse width and voltage) were set by the pro-
grammed protocol 2 weeks after implantation to achieve 
the best control of symptoms without adverse side effects 
[18].
PET images and preprocessing
In our study, all participants were asked to fast for at 
least 6  h but had free access to water prior to 18F-FDG 
PET scanning. All patients underwent scanning at least 
12 h after the cessation of oral antiparkinsonian medica-
tions. Subjects from cohort I were scanned on a Siemens 
Biograph 64 PET/CT (Siemens, Erlangen, Germany) in 
three-dimensional mode. After a CT transmission scan 
for attenuation correction, a PET image was acquired 
over 45–55  min post-injection of 18F-FDG (8–10  mCi) 
and was reconstructed with the ordered subset expecta-
tion maximization method. Individuals from cohort II 
were scanned with a GE Advance Tomograph (General 
Electric, Milwaukee, WI, USA) in 3D mode. The patients 
in this cohort underwent PET scanning in the STN DBS 
“OFF” state (as above, the absence of STN stimulation 
for at least 2 h prior to PET scanning). Following a trans-
mission scan, a PET image was acquired over 45–55 min 
after an intravenous injection of 18F-FDG (8–10  mCi) 
and was reconstructed with the 3D reprojection method. 
Table 1 Demographic and clinical characteristics of healthy controls and PD patients
Data are given as mean ± standard deviation
UPDRS Unified Parkinson’s Disease Rating Scale
Cohort Gender
(M/F)
Age
(years)
Duration 
of disease 
(years)
UPDRS PDRP Z-score
Preoperative baseline Post-operation Preoperative baseline Post-operation
3 months 12 months 3 months 12 months
Cohort I
HC1 15/18 57.4 ± 10.5 – – – – 0 ± 1.0 – –
PD1 15/18 58.1 ± 10.3 4.3 ± 4.1 25.2 ± 14.4 – – 2.74 ± 1.18 – –
Cohort II
HC2 4/5 61.7 ± 7.3 – – – – 0 ± 0.52 – –
PD2 (patients underwent DBS)
1 F 50 8 49 21 60 3.01 0.11 1.83
2 M 66 19 62 53 69 1.61 − 0.18 0.17
3 M 62 10 51 10 37 2.42 1.97 2.28
4 F 72 5 50 12 31 1.52 − 0.40 0.39
5 M 53 17 39 30 – 4.21 2.84 –
6 F 54 13 52 31 – 2.89 2.77 –
7 F 77 7 51 24 – 3.71 2.53 –
8 F 69 4 58 56 – 2.69 2.11 –
9 M 65 6 35 10 – 0.72 0.26 –
Total 4/5 63.1 ± 9.2 9.9 ± 5.3 49.7 ± 8.4 27.4 ± 17.3 49.3 ± 18.2 2.53 ± 1.11 1.33 ± 1.35 1.17 ± 1.04
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All subjects were scanned in a resting state with the eyes 
open in a quiet and dimly lit room.
Preprocessing of brain PET images from each partici-
pant was performed using Statistical Parametric Map-
ping software (SPM8) implemented in MATLAB 9.1.0 
(MathWorks Inc, Sherborn, MA). The images were spa-
tially normalized into the Montreal Neurological Insti-
tute (MNI) brain space with linear and nonlinear 3D 
transformations. The normalized PET images were then 
smoothed by a Gaussian filter of 8-mm FWHM over a 
3D space to increase the signal-to-noise ratio for statisti-
cal analysis. Local metabolic activity normalized to global 
activity was measured in 95 regions of interest (ROIs). 
In addition to 90 ROIs from the automated anatomical 
labeling (AAL) atlas [19], this analysis included 5 discrete 
ROIs corresponding to the vermis, bilateral cerebellum 
(excluding the vermis) and bilateral pons [7].
Pattern analysis
To identify a significant PDRP topography, we applied the 
Scaled Subprofile Model and Principal Component Anal-
ysis (SSM/PCA) to 18F-FDG PET images from combined 
PD1 patients and HC1 subjects in cohort I using Scan 
Analysis and Visualization Processor (ScAnVP software 
V6.0, software package available on https ://www.feins 
teinn euros cienc e.org at the Center for Neuroscience, 
Feinstein Institute for Medical Research, NY) [20]. This 
analysis was done through a regional approach analogous 
to that described previously, in which subject × voxel 
covariance analysis of group-level image data was applied 
to measurements of metabolic activity using an auto-
mated computerized algorithm [21, 22]. The PDRP pat-
tern was acquired by the first principal component (PC1), 
whose expression could discriminate PD patients from 
healthy subjects. The reliability of voxel weights on the 
PDRP pattern was assessed using bootstrap resampling 
described previously [23]. The procedure entails per-
forming the SSM/PCA method 100 times on PET data 
that were resampled with replacement from the pool of 
PD and HC subjects. Next, the Z-score of each voxel was 
calculated, and the threshold of 3.35 was used to meas-
ure the reliability of voxel weight. The expression of the 
PDRP pattern of each subject was calculated using the 
topographic profile rating (TPR) algorithm and repre-
sented by a Z-transformed score using scores of the HC1 
subjects [6]. The DBS treatment effects of PD patients 
were represented predominantly by PDRP expression 
changes. These expression scores were also Z-trans-
formed using scores of HC1 subjects and subtracting the 
offset value of HC2 to eliminate the effects of different 
scanning devices.
The derived metabolic topography was further assessed 
by an ROI-based pattern of regional weights in a set of 
salient abnormal brain regions. Therefore, we measured 
the PDRP regional weights and identified the salient 
abnormal regions. In brief, the PDRP regional weights 
were derived by the mean standardized voxel weights 
within an ROI and then Z-transformed based on the 
mean and standard deviation of 95 predefined ROIs. We 
then divided the brain into disease subspace and non-
subspace based upon the ROI-wise weights, correspond-
ing, respectively, to ROIs with high (absolution region 
weight greater than or equal to 1) and low (absolution 
region weight below 1) local contributions to the overall 
PDRP pattern [15].
Graph theory-based brain connectome analysis
To better understand the pattern variation within PDRP 
concurrent with STN DBS treatments over a relatively 
long time period, graph theory-based brain connectome 
analysis was implemented for cohort II. This analysis has 
been widely applied to reveal the changes of local neu-
ral functional connectivity in neurodegenerative diseases 
[12–14, 24]. In this study, the 18F-FDG PET image signals 
in ROIs reflected metabolic synaptic activity. A graphical 
network representation of inter-ROI coherence was con-
structed. Network nodes in each network were defined 
as the 95 standardized predefined ROIs. Network con-
nectivity was defined as metabolic correlations between 
pairs of network nodes that denote interneuronal infor-
mation transfer [25]. The metabolic activity in each of the 
ROIs was used to generate a region × region correlation 
matrix (95 × 95 for PD2 and HC2 groups). The correla-
tion matrix based on absolute values of pairwise regional 
correlation coefficients was constructed for each group 
by Pearson correlation. Then, the adjacency matrices 
(binary, undirected matrices) were generated from the 
absolute correlation matrix at varying sparsity thresholds 
(1–50%, 1% as the threshold interval), where the sparsity 
threshold is defined as the connection density, which is 
the ratio of existing connections to possible connections 
[15]. We calculated the minimum sparsity threshold of 
fully connected data for the PD2 and HC2 groups.
For all experimental groups, we calculated three net-
work properties as follows: (1) the clustering coefficient 
(C), which is a measure quantifying the degree to which 
nodes in a network tend to cluster together and is a rep-
resentation of network segregation, measuring the local 
information transmission capability in a network [26]; (2) 
the characteristic path length (L), which is a measure of 
network efficiency defined as the average shortest path 
length on the graph, measuring the global information 
transmission capability in a network; and (3) the small-
worldness coefficient (S), which is the C/L ratio for the 
graph divided by the analogous measure for a random 
graph with the same sparsity [27]. To avoid biases related 
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to a single threshold, the above-mentioned properties 
were computed at varying sparsity thresholds, stepwise 
by 0.01 intervals.
In our study, differences in the analytical parameters 
were evaluated separately for the PDRP and non-PDRP 
spaces of the experimental groups, as well as correspond-
ing group × subspace interaction effects. This analysis 
was performed with 1000 permutations of random sam-
ples from the combined subject pool at each sparsity 
threshold. Graph theoretic measures were performed 
using the Brain Connectivity Toolbox (https ://www.brain 
-conne ctivi ty-toolb ox.net/) [28].
Statistical analysis
Differences of PDRP expression between PD and HC 
subjects in each cohort were evaluated by two-sample 
Student’s t test. The changes in PDRP scores and UPDRS 
motor ratings were evaluated using one-way repeated-
measure ANOVA (RMANOVA) with post hoc Bonfer-
roni tests across 3 follow-up intervals. We also used 
paired-samples t tests when comparing PDRP scores and 
UPDRS motor ratings between the first and the second 
follow-up intervals. The network properties for the PDRP 
subgraphs and the differences between the subgraphs 
were compared across samples using permutation tests. 
All statistical analyses were performed using SPSS 22.0 
software (SPSS Inc., Chicago, IL) run on a Windows plat-
form. Values were considered significant at P < 0.05 with 
2-tailed tests.
Results
PDRP identification and expression
Pattern analysis of individual 18F-FDG PET images in 
cohort I identified ROI-based PDRP with the first prin-
cipal component, which accounted for 17.99% of sub-
ject × voxel variance. This pattern was characterized 
by relative metabolic increase in the putamen, palli-
dum, caudate, thalamus, cerebellum, pons and olfactory 
region, associated with metabolic decrease in the poste-
rior parietal–occipital cortices (Fig. 1a).
The scores of PDRP expression were abnormally ele-
vated in PD1 patients compared with HC1 subjects 
(P < 0.001; two-sample t tests; Fig. 1b). Similarly, prospec-
tively computed PDRP scores of PD2 patients at preoper-
ative baseline were also increased (P < 0.001; two-sample 
t  tests; Fig.  1b) relative to those of HC2 subjects. For 
the PD2 patients, the trend in individual values for the 
UPDRS motor rating and PDRP expression at three time-
points (preoperative baseline, 3-month post-operation 
and 12-month post-operation), both exhibited significant 
Fig. 1 a PDRP identified by pattern analysis in 18F-FDG PET images from PD1 patients and HC1 subjects. This pattern was characterized by relatively 
higher metabolism in the bilateral putamen, pallidum, caudate, thalamus, cerebellum, pons and olfactory region, which was associated with 
decreased metabolism in the posterior parietal–occipital cortices. Regions with metabolic increases (positive region weights) are color-coded from 
red to yellow; those with metabolic decreases (negative region weights) are color-coded from blue to purple. b The expression of the PDRP pattern 
showed that the subject scores of PD patients were relatively higher than those of HC subjects in both cohort I and cohort II (P < 0.001). UPDRS 
motor ratings (c) and PDRP scores (d) in PD2 patients at preoperative baseline, 3-month post-operation and 12-month post-operation in STN DBS 
“OFF” states both exhibited significant changes across intervals (P < 0.01; RMANOVA). The scatters of different colors and shapes represent the PD 
patients with DBS treatment
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changes in activity over time (UPDRS: F(2,6) = 11.101, 
P = 0.010; PDRP: F(2,6) = 10.596, P = 0.011; RMANOVA), 
are summarized in Table  1, Fig.  1c, d. Indeed, we 
observed a significant decrease in UPDRS (P = 0.028, 
post hoc test; P = 0.001, paired-sample t  tests; Fig.  1c) 
and PDRP scores (P = 0.039, post hoc test; P = 0.004, 
paired-sample t  tests; Fig.  1d) from baseline to the sec-
ond follow-up timepoint, but a slight increase from the 
second to the third timepoint (UPDRS: P = 0.016; PDRP: 
P = 0.094, post hoc test). The changes in PDRP expres-
sion mediated by STN DBS were generally in line with 
improvement of UPDRS motor ratings in PD2 patients. 
For the UPDRS motor ratings, 2 of the 4 PD2 patients 
showed higher scores at the third timepoint with respect 
to baseline, whereas the other 2 patients had slightly 
lower scores at the third timepoint relative to baseline. 
For PDRP expression, all 4 patients showed relatively 
lower scores at the third timepoint compared with those 
at baseline.
Graph-theory-based analysis
Graph-theory-based analysis was also used to disclose 
the longitudinal changes in network measures in PD 
patients who underwent STN DBS at different follow-up 
intervals. For this analysis, the whole brain was divided 
into 2 discrete subspaces (PDRP and non-PDRP sub-
spaces) depending on the region weights. We high-
lighted PDRP subspaces with 29 ROIs, in which 13 ROIs 
had positive region weights that were greater than + 1.0, 
while the other 16 ROIs had negative region weights that 
were lower than − 1.0 (Additional file 1: Table S1). In all 
participant groups, the minimum sparsity threshold in 
which the network was fully connected was calculated: 
10% (PD2, preoperative baseline), 25% (PD2, 3-month 
post-operation), 12% (PD2, 12-month post-operation) 
and 12% (HC2). The network properties were calculated 
at various sparsity thresholds in the range of 25–50% for 
PD2 and HC2.
With the analysis of the network properties for PDRP 
subspaces at a sparsity threshold of 25% (Fig. 2a, b), the 
clustering coefficient (C) of PD2 at the preoperative 
baseline increased compared with that of HC2 (HC2: 
C = 0.468; PD2-baseline: C = 0.587). In contrast, the char-
acteristic path length (L) of PD2 at preoperative baseline 
decreased relative to HC2 (HC2: L = 1.965; PD2-baseline: 
L = 1.633), with corresponding increases in the small-
worldness coefficient (S) (HC2: S = 1.335; PD2-base-
line: S = 1.877). The difference in the PDRP subspaces 
between HC2 and PD2 at preoperative baseline was 
significant given the sparsity threshold (P < 0.05; 1000 
permutations).
With the analysis of the network properties within 
PDRP subspaces for PD2 patients at 3 different follow-up 
intervals under a sparsity threshold of 25% (Fig.  2b–d), 
the small-worldness coefficient decreased from base-
line to the second timepoint, but increased between the 
second and third timepoints (PD2-baseline: S = 1.877; 
PD2-3  months: S = 1.667; PD2-12  months: S = 2.016). 
Analogous measure differences were also discovered 
for the clustering coefficient (C) and the characteris-
tic path length (L) (PD2-baseline: C = 0.587, L = 1.633; 
PD2-3  months: C = 0.574, L = 1.546; PD2-12  months: 
C = 0.680, L = 1.774). The difference in the PDRP sub-
spaces between baseline and 3-month post-operation, 
and between 3-month post-operation and 12-month 
post-operation was all significant given the sparsity 
threshold (P < 0.05; 1000 permutations). In addition, the 
network properties of each group, over the entire sparsity 
threshold range (25–50%), are shown in Additional file 1: 
Fig. S1.
Discussion
This study demonstrated metabolic network can capture 
the longitudinal changes of PD patients who had under-
gone STN DBS treatment. Clinical assessments of our 
cases post-operation at 3-month follow-up showed that 
electrical stimulation markedly improved motor func-
tion of each patient by an average 46% compared with 
that at baseline prior to the surgery, whereas followed by 
a reversal of UPDRS performance at 12-month follow-up. 
Such trend of UPDRS scores, which is positively corre-
lated with changes in corresponding PDRP expression, 
suggesting the latter may provide a complementary bio-
marker for the measurement of the treatment outcome.
This study attempted to capture the individual cor-
relation between motor performance and PDPR expres-
sion, which was proposed to represent inherent brain 
metabolic changes of PD patients by long-term STN DBS 
intervention. Significant instantaneous suppression of 
cerebral metabolism during effective antiparkinsonian 
therapies (e.g., DBS stimulation or titrated intravenous 
levodopa infusion) has been reported previously [10]. 
Although the investigation of instantaneous effect during 
intervention is important to understand the mechanism 
of the external stimuli on brain function, the ultimate 
treatment effects may not be revealed due to the sup-
pression of instantaneous effect. Therefore, this longitu-
dinal study investigated PET images in the “OFF” state 
instead of the “ON” state of the treatment. The PET scans 
were acquired at least 2 h after the STN stimulation. This 
allowed us to observe more stable treatment effect rather 
than instantaneous changes during the STN stimulations.
The strong correlation between PDRP expression and 
measures of the motor disability rating scale was coin-
cidentally reported in previous studies [13, 29]. Thus, 
it is not surprising that changes of pattern expression 
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were observed in general consistent with corresponding 
UPDRS motor ratings in this longitudinal study. Particu-
larly, we found that pattern scores in subjects who under-
went STN DBS were significantly downward modulated 
from baseline to 3-month post-operation. This finding 
agreed with the results of previous trials, showing that 
stimulation intervention (targeting at STN, GPi and 
PPN) produced marked suppression of PDRP activities in 
advanced PD. Similar changes in PDRP expression have 
also been observed during levodopa infusion as well as 
STN lesioning surgery as a reflection of therapeutic ame-
lioration [30, 31]. During the longer follow-up, the PDRP 
expression, while kept pace with motor scores, regretta-
bly rebounded, suggesting that STN DBS may exert the 
best corrective effect in a relative short-term post-opera-
tion. Although the changes of PDRP expression generally 
correlate with the changes of UPDRS score, we noted the 
trajectories of the two indices revealed some difference, 
with greater rollback in UPDRS motor ratings compared 
to corresponding PDRP expression in the same patients. 
It is conceivable that the relatively modest fluctuation 
in PDRP expression observed in this study is a reflec-
tion of cerebral modulation of motor function. Longitu-
dinal stimulation of STN may not show a continuously 
significant suppression on symptomatic motor signs but 
instead exerts its benefit by inducing the reinforcement 
of motor circuit connecting the STN to subcotical and 
cortical motor regions. In this way, PDRP as an objective 
criteria may provide complimentary insight for treatment 
monitoring.
Graph theory also provided network-level insights into 
the flow of information through the PDRP subspaces. 
We observed PD patients at baseline with greater clus-
tering and lower path length within the context of PDRP 
Fig. 2 The metabolic connection network of HC2 subjects (a), PD2 patients at baseline (b), PD2 patients at 3-month post-operation (c), PD2 
patients at 12-month post-operation (d) in PDRP subspaces at a sparsity threshold of 25%. The blue circle nodes indicate different anatomical brain 
regions. Red and green lines indicate pathological (i.e., significantly altered, P-value with FDR correlated < 0.05) and normal metabolic connection 
between brain regions of PDRP subspaces
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subspaces, giving rise to an increase in the small-world 
coefficient compared with the corresponding value for 
healthy subjects. An analogous elevation in small-world-
ness was previously delineated in a separate 18F-FDG 
PET study that involved a similar cohort of clinically veri-
fied PD subjects; for the first time, this study proposed 
an association between the exaggerated small-worldness 
underlying PD and the high metabolic costs and ineffi-
ciency, as well as noisy information transfer among PDRP 
subspaces [13, 15]. Our results also showed PDRP sub-
spaces with decreased small-worldness coefficient toward 
normal at 3  months, suggesting STN-DBS stimulation 
tended to exert a normalizing effect that could minimize 
the resources required for effective information process-
ing and communication within the PDRP subspaces in 
the early stage after DBS treatment. These changes were 
in agreement with the results of previous studies show-
ing the beneficial effects of levodopa in partially correct-
ing small-worldness in PDRP in individual patients [15]. 
Nonetheless, we also noted a significant rebound in this 
measure in the subsequent follow-up period, with even 
higher values of 12-month post-operation compared with 
the preoperative baseline. This variation tendency was 
consistent with the changes in PDRP expression over 
time, as mentioned above, and further indicated that 
DBS may exert a relatively short-term corrective effect on 
functional connectivity in PD brains rather than a long-
term impact.
Furthermore, conventional ROI standard uptake value 
ratio (SUVR) analysis underlying PDRP subspaces is also 
calculated in Additional file 1: Table S2. The quantifica-
tion of SUVR and PDRP scores actually portrayed differ-
ent but complementary measures of brain dysfunction, 
with the former emphasizing on regional analysis and the 
latter tending to be a network analysis. Thus, the applica-
tions of both quantitative indexes may provide more val-
uable information to describe changes of brain function 
induced by treatment at both regional and global levels.
Several limitations of this study should be noted: (1) 
In the absence of a neuropathological confirmation 
of PD in our patient cohorts, we relied on the clinical 
diagnostic accuracy of movement disorder experts. 
This decision was a valuable strategy that reflected how 
PD is diagnosed in the real world. (2) The sample sizes 
of PD patients who underwent STN DBS in the cur-
rent study were relatively small. These limited samples 
might be justifiable, given that this is a pilot study to 
first investigate longitudinal changes in whole brain 
network activities associated with PD patients who 
underwent STN DBS. Nonetheless, the limited sam-
ple size may result in sufficient statistical power. It will 
be necessary to replicate the results reported here in 
similar patients with larger sample sizes. (3) The rela-
tionship between brain glucose metabolism and clini-
cal measures of treatment outcomes more than 1  year 
after DBS surgery has not been fully demonstrated due 
to the limited length of follow-up. While we observed 
the best performance in network measures in individ-
ual patients at the 3-month rather than the 12-month 
post-operation timepoint, we estimated a probable 
declined treatment effect of DBS stimulation as disease 
evolved by the asymmetry of DBS lead localization. (4) 
This study only investigated the longitudinal changes of 
PD patients with STN DBS “OFF” stage; future study 
will put more attention to the results of STN DBS “ON” 
stage.
Conclusion
This study confirmed significant correlation between 
PDRP expression and UPDRS motor ratings by long-
term STN DBS stimulation in PD patients. Reduced 
metabolic activity of brain network, in consistent with 
UPDRS motor function, was significant at the 3-month 
post-operation timepoint relative to baseline, but with 
less dramatic effects at the 12-month post-operation, 
indicating the short-term effect produced by STN 
DBS better than long-term effect. Taken together, our 
results demonstrate the potential of PDRP expression 
as a complimentary objective biomarker for the indi-
vidual assessment and monitoring of STN DBS treat-
ment outcome for PD.
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